Bioinformatics Protein RNA Scientist 
Drug Discovery World
OCTOBER 26, 2023
The technologies cover the whole range of biomolecules from genes to protein to metabolites. Using classical bulk (deep) RNA-Seq on thousands of human blood and tissue samples, Evotec has been building a high-quality molecular patient database – E.MPD. phosphorylations or ubiquitinations).
Drug Discovery World
APRIL 6, 2023
The workshop will be led by hfp consulting, a firm which specialises in career development and leadership training for scientists. These topics will be represented across a range of session types, including methods workshops, minisymposia, poster and plenary sessions, as well as keynotes, awards and lectures.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Discovery World
NOVEMBER 13, 2023
Ahead of protein and antibody engineering conference PEGS Europe 2024 in Lisbon, DDW’s Megan Thomas looks at what to expect from each track of the annual biologics technology meeting. Ali Madani, PhD, Founder and CEO, Profluent Bio, on: ‘Protein engineering with large language models’.
Drug Discovery World
JULY 11, 2023
Now, with the growth of publicly available genomics, transcriptomics, and proteomics databases, the ability to quickly carry out large-scale DNA, RNA, and protein screenings, and the availability of massive sets of de-identified patient data, the amount of high-value, analysable data has reached enormous proportions.
Drug Discovery World
FEBRUARY 6, 2023
Johannes Goll, Global Head of Emmes’ Biomedical Data Science and Bioinformatics department, explains how big data analytics can deliver improved therapies and bring clinical research one step close to realising the potential of personalised care. Figure 2: Advanced data visualisation examples for transcriptomics data.
Drug Discovery World
APRIL 14, 2023
DDW Editor Reece Armstrong speaks to Nautilus Co-Founder and Chief Scientist Parag Mallick , about the company’s recent collaboration which aims to uncover the proteins that could be behind a rare and fatal childhood cancer. These mutated proteins then reprogramme the epigenome, from which the cancer develops.
Drug Discovery World
NOVEMBER 30, 2023
This presentation covered three primary drivers for a protein expression model: speed, cost and sustainability. “It The next presentation attended in this track was the keynote presentation, which was given by Kate Smith, PhD, Head of UK Protein & Cell Sciences at GSK. GSK has developed high-throughput mammalian and E.
Expert insights. Personalized for you.
52 
Let's personalize your content